In Focus: AAV gene therapy
Adeno-associated viruses (AAVs) are rapidly becoming a promising means of delivering gene therapies to defective tissues in the human body. To this end, scalable and cost-effective AAV vector production is critical to meet commercial demand during the gene therapy production process. The viral vector workflow requires a smooth scale-up to clinical production to develop breakthrough cell and gene therapy.
In this In Focus feature, which has been produced in association with Thermo Fisher Scientific (CA, USA), we explore the various production systems that enable companies to streamline their transition from research to the clinical scale.
In association with:
